Trial reportInternational journal of obesity (2005)2024
The effect of GLP-1 receptor agonist use on negative evaluations of women with higher and lower body weight.
Trial report in International journal of obesity (2005), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- An experimental investigation of the stigmatization of weight loss and regain from GLP-1 receptor agonist use and cessation.International journal of obesity (2005) · 2026Trial
- Exposure to GLP-1 Receptor Agonist and Bariatric Surgery Use on Obesity Policy Support.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2024Trial
- Behavior change support in the new era of obesity care.BMC medicine · 2026Article
- Article
- Beyond weight loss: Integrating GLP-1 RA therapies into psychological and behavioral care for obesity and binge eating disorder.Reviews in endocrine & metabolic disorders · 2026Review
- Social Perceptions of Weight Loss With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Black and White Women With Obesity.Stigma and health · 2026Article
- Anti-obesity medication use sparks effort-based sanctions and social penalties.Scientific reports · 2026Article
- Widespread exposure to GLP-1RAs and weight loss-related discourse: Considering potential public health implications.Canadian journal of public health = Revue canadienne de sante publique · 2026Article
- Changes in how people living with obesity perceive weight-related discussions with their healthcare professional: Results from the cross-sectional online ACTION-DK 2022 and 2024 studies.Diabetes, obesity & metabolism · 2026Article
- Drugs, diet, or surgery? How treatment type and willpower shape responsibility for weight loss and judgments of the physician and treatment.Frontiers in psychology · 2026Article
- Revisiting food addiction in the era of GLP-1-based obesity pharmacotherapy via neural reward pathways linking feeding and substance use.Frontiers in behavioral neuroscience · 2026Review
- Primary Care Providers Perspectives of GLP-1 Receptor Agonists to Manage Recurrent Weight Gain after Metabolic Bariatric Surgery - a Qualitative Study.Obesity surgery · 2026Article
- Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes.Nutrients · 2025Review
- GLP-1 Receptor Agonists for Treatment of Pediatric Obesity: Behavioral Health Considerations.Childhood obesity (Print) · 2025Review
- Article
- Views Among the General Public on New Anti-Obesity Medications and on the Perception of Obesity as a Failure of Willpower.Obesity science & practice · 2025Article
- The Impact of Novel Medications for Obesity on Weight Stigma and Societal Attitudes: A Narrative Review.Current obesity reports · 2025Review
- Behavioral medicine in the GLP-1 era.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2025Article
- Tackling the complexity of obesity in the US through adaptation of public health strategies.Frontiers in public health · 2025Review
- Beyond the prescription: Global observations on the social implications of GLP-1 receptor agonists for weight loss.PLOS global public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundGLP-1 receptor agonists (GLP-1 RAs) have dramatically altered obesity treatment. Media reports suggest that GLP-1 RAs users often report feeling judged for taking a "shortcut" to lose weight, which may be related to negative stereotypes toward people with larger bodies. Media reports also describe negative attitudes about lean people who take GLP-1 RAs to enhance their appearance. The present research used a 2 × 2 experimental design to test the effects of GLP-1 RA use and body size on attitudes and egocentric impressions. SUBJECTS/
methodsA sample of 357 U.S. adults (M
resultsNegative evaluations and egocentric impressions were stronger toward a woman who lost weight with a GLP-1 RA compared to diet/exercise. Losing weight with a GLP-1 RA led to stronger negative evaluations through higher weight loss shortcut beliefs irrespective of body size. Losing weight with a GLP-1 RA also led to higher egocentric impressions through higher shortcut beliefs, and this effect was stronger for a lean woman. Finally, losing weight with a GLP-1 RA led to more negative evaluations through stronger endorsement of biogenetic causal beliefs for a lean woman only.
conclusionsThis timely study provides evidence that people with larger and smaller bodies alike are at-risk for being judged for using GLP-1 RAs due to beliefs that these medications are a shortcut. Findings also demonstrate novel reactions related to egotism when weight loss is achieved with pharmacological interventions. PRE-REGISTRATION AND DATA: osf.io/xme4w.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.